FDA authorizes Merck’s oral HIV regimen and adds new coverage options

The FDA has approved Merck & Co.’s once-daily HIV pill, strengthening the company’s push to remain a major HIV drug supplier as more biotechs have exited the space. The approval adds a new treatment option for adults with HIV-1 infection, positioning the regimen as part of Merck’s broader strategy in antiretroviral therapy.